Objective: The purpose of this study was to identify the clinical factors associated with time to hCG remission among women with low-risk postmolar GTN.
Methods: This study included a non-concurrent cohort of 328 patients diagnosed with low-risk postmolar GTN according to FIGO 2002 criteria. Associations of time to hCG remission with history of prior mole, molar histology, time to persistence, use of D&C at persistence, presence of metastatic disease, FIGO score, hCG values at persistence, type of first line therapy and use of multiagent chemotherapy were investigated with both univariate and multivariate analyses.
Results: Overall median time to remission was 46 days. Ten percent of the patients required multi-agent chemotherapy to achieve hCG remission. Multivariate analysis incorporating the variables significant on univariate analysis confirmed that complete molar histology (HR 1.45), metastatic disease (HR 1.66), use of multi-agent therapy (HR 2.00) and FIGO score (HR 1.82) were associated with longer time to remission. There was a linear relationship between FIGO score and time to hCG remission. Each 1-point increment in FIGO score was associated with an average 17-day increase in hCG remission time (95% CI: 12.5-21.6).
Conclusions: Complete mole histology prior to GTN, presence of metastatic disease, use of multi-agent therapy and higher FIGO score were independent factors associated with longer time to hCG remission in low-risk GTN. Identifying the prognostic factors associated with time to remission and effective counseling may help improve treatment planning and reduce anxiety in patients and their families.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2013.05.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SEVERE DISEASE PROGRESSION OF POSTMOLAR GESTATIONAL NEOPLASM IN A VIETNAMESE YOUNG FEMALE PATIENT AFTER TREATMENT REFUSAL: INSIGHTS FROM A CASE REPORT AND LITERATURE REVIEW.
Exp Oncol
October 2024
Tu Du Clinical Research Unit, Tu Du Hospital, Ho Chi Minh City, Vietnam.
Article Synopsis
- - Choriocarcinoma is a highly aggressive but treatable form of gestational trophoblastic neoplasm, which can lead to severe health issues, including massive hemorrhage and death, particularly in women of childbearing age with high-risk scores.
- - A case study highlights a 20-year-old woman with widespread metastatic choriocarcinoma who lapsed in treatment due to the COVID-19 pandemic, resulting in severe complications like intraabdominal hemorrhage that required immediate surgery.
- - Despite being in a coma and on a ventilator, the patient successfully underwent multiagent chemotherapy, initially with the EMA/CO regimen followed by the TP/TE regimen, leading to a significant decrease in her β-hCG levels,
Revealing the Unanticipated: An Uncommon Case of Colorectal Adenocarcinoma Transitioning to Choriocarcinoma - A Case Report and Literature Review.
Eur J Case Rep Intern Med
September 2024
Department of Hematology/Oncology, Texas Tech University Health Science Center, Lubbock, USA.
Unlabelled: Choriocarcinomas are uncommon tumors, with non-gestational types occurring in both males and females. Primary choriocarcinoma of the colon is extremely rare. It presents significant diagnostic and therapeutic challenges due to its aggressive nature and poor prognosis, with no cure available, and a mean survival of 8 months.
View Article and Find Full Text PDFTreatment of High-Risk Gestational Trophoblastic Neoplasia.
Hematol Oncol Clin North Am
December 2024
New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
High-risk gestational trophoblastic neoplasia encompasses patients with high volumes of disease or diffuse metastatic involvement who are unlikely to achieve remission with single-agent chemotherapy. Etoposide-based multi-drug regimens form the core of high-risk therapy. Second-line therapy includes platinum-based regimens.
View Article and Find Full Text PDFFertility-sparing surgical interventions for low-risk, non-metastatic gestational trophoblastic neoplasia.
Cochrane Database Syst Rev
September 2024
Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Article Synopsis
- The primary treatment for low-risk nonmetastatic gestational trophoblastic neoplasia (LR-NMGTN) is chemotherapy, but fertility-sparing surgical options may provide benefits like fewer side effects and a faster remission time.
- The aim of the study is to compare the effectiveness and risks of fertility-sparing surgical interventions, with or without chemotherapy, against standard chemotherapy for women with LR-NMGTN.
- The research involved searching various medical databases for randomized controlled trials, ultimately analyzing data from two studies with 151 participants to evaluate treatment outcomes and quality of life.
Tislelizumab for treatment of a pediatric patient with primary mediastinal choriocarcinoma: a case report.
Transl Pediatr
August 2024
Department of Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Article Synopsis
- Primary mediastinal choriocarcinoma (PCC) is a rare and aggressive tumor usually found in midline areas like the mediastinum, with no established treatment guidelines currently in place.
- A case involving a 15-year-old boy with severe symptoms and a large mediastinal mass revealed elevated tumor marker levels, indicating a germ cell tumor with lung metastasis.
- Treatment included chemotherapy and tislelizumab, resulting in significant improvement in symptoms and a decrease in beta-HCG levels, with the patient still alive as of March 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!